Mumbai: Indian healthcare major Piramal, which had taken over Bayer HealthCare’s molecular-imaging pipeline, has been investing in German molecular imaging technology.
With the Indian major of the belief that the future of medicine is set to be personalised medicine, the global deal inked in April this year is set to help in the early detection of Alzheimers.
Piramal Enterprises sees revenue potential of $1.5 billion from its florbetaben molecule. Piramal had taken over the pipeline from the German company and has since then been continuing research and development work on the acquired PET (Positron Emission Tomography) which is a nuclear medicine imaging technique at its labs in Berlin.
At a press briefing, Ajay Piramal, Chairman of the Piramal Group commented on the strategy, “Molecular imaging is one of the key technologies paving the way for individualised medicine. Our acquisition of a powerful pipeline in this field is an important milestone on the road to an innovative pharmaceutical portfolio.”
Florbetaben, Piramal’s most advanced PET tracer, enables the detection of beta-amyloid deposits in the brain.
“A phase III study to test the reliability of florbetaben in the histopathological detection of beta-amyloid has been successfully completed. Submission of the dossier for drug approval by the US Food and Drug Administration and the European Medicines Agency is expected later in 2012.
“In addition, Piramal Imaging is working on other PET tracers for various medical indications,” said Swati Piramal, Vice-Chairperson of Piramal Enterprises.
Christoph von Knobelsdorff, Permanent Secretary at the Berlin Senate’s Department of Economics, Technology and Research, said Piramal Imaging’s decision to come to Berlin was a real gain for the city
No comments:
Post a Comment